logo
Judge Allows Docs' Lawsuit Against MultiPlan to Proceed

Judge Allows Docs' Lawsuit Against MultiPlan to Proceed

Medscapea day ago

A district judge has ruled that physicians can move forward with a federal lawsuit that accuses insurers and an analytics company of underpaying them by billions through a price-fixing scheme for out-of-network services.
In a June 3 decision, US District Judge Matthew Kennelly wrote that providers have alleged a direct injury from the reported price-fixing agreement and that their antitrust claims against data company MultiPlan are valid.
The ruling addresses two consolidated complaints by several plaintiffs, including the American Medical Association (AMA) and the Illinois State Medical Society (ISMS), against MultiPlan, which has now changed its name to Claritev.
The medical associations claim MultiPlan/Claritev and third-party payers violated federal and state antitrust laws with a price-fixing conspiracy that forced physicians to accept increasingly low payments for out-of-network services. The suit names Aetna, Cigna, UnitedHealth Group, and Health Care Service Corporation, a Mutual Legal Reserve Company, as 'co-conspirators' in the complaint, among other 'smaller' insurers.
AMA President Bruce A. Scott, MD, praised the court for allowing the case to proceed, calling the ruling 'the clearest statement yet by a court that MultiPlan's lack of transparency, accuracy, and integrity in the insurer-run system for paying out-of-network medical bills is an antitrust violation.'
'MultiPlan and the commercial health insurance companies have profited from the rigged system while forcing physicians to accept lower and lower payment amounts for out-of-network services — payments that in many cases do not cover the cost of delivering care to patients,' Scott said in a media statement. 'Ending this conspiracy is a good start toward creating an open and honest system that will restore fair reimbursements and help ensure patients have access to the care they need.'
A Claritev spokeswoman told Medscape Medical News in an email that the company remains 'confident that the facts will reinforce what we've consistently said — that these lawsuits are without merit and fail to acknowledge the critical role our competitive options play in reducing healthcare costs for employers and improving access for patients.'
'These lawsuits will only serve to increase healthcare [costs] for employers and patients. We will vigorously defend ourselves through the legal process while remaining focused on delivering value to our customers and the broader healthcare ecosystem.'
ISMS President Richard C. Anderson, MD, said the medical society appreciates the ruling and that it's 'time for MultiPlan to face the music.'
'The company can change its name, but it doesn't change the fact that they reaped huge profits from this price-fixing collusion,' Anderson wrote in an email to Medscape Medical News . 'They routinely paid below-market reimbursement rates to physician for out-of-network healthcare services with no transparency in their process. Patients and physicians deserve better.'
Alleged Price-Fixing Conspiracy
On its website, Claritev describes itself as a healthcare technology, data, and insights company that focuses on improving affordability, transparency, and quality.
The company offers an alternative method for calculating a third-party payer's out-of-network rate through its Data iSight algorithm, according to court records. Data iSight calculates rates by referencing the cost of the service to the provider and the median payment for similar services rendered, according to the legal summary. Using these metrics, the algorithm tends to produce lower payment rates than Usual, Customary, and Reasonable benchmarks.
If payers agree to use a Data iSight-calculated rate, the company offers to negotiate the rate with providers on behalf of the insurer. During the negotiation, MultiPlan/Claritev conditions all payments on a provider's agreement not to balance bill the patient, according to the legal summary.
The plaintiffs allege the company's rates are provided on a 'take-it-or-leave-it' basis and that they were unable to convince the company to deviate from a Data iSight-calculated rate.
Providers can still decline MultiPlan's offer and seek payment directly from the patient and the insurer, according to court documents.
An April 2020 study by the Office of the New York State Comptroller found that payments based on MultiPlan's repricing methodology at the time were 1.5-49 times lower than payments for the same services based on the traditional method of calculating out-of-network payment rates for physicians, according to the AMA.
The physician plaintiffs contend the company undercuts fair payment for out-of-network healthcare services and eliminates market competition. The 'widespread conspiracy' between the company and insurers has forced many medical practices to shut down, cease offering certain services, or seek other employment arrangements, according to their complaint.
Insurers have contracted with MultiPlan to use its Data iSight algorithm and negotiation services since 2015, and by 2018, hundreds of third-party payers had contracts with the company, according to court records. The company grew to having contracts with more than 700 third-party payers and, in 2019, processed more than 80% of out-of-network healthcare service payments, according to court documents.
A 2024 New York Times investigation found that both the company and insurers made more money when then-MultiPlan lowered fees paid to physicians for out-of-network services. In May 2024, Ron Wyden (D-Oregon) and Bernie Sanders (I-Vermont), US senators, requested more information from MultiPlan, expressing concern that the company might be driving up costs for consumers.
Sen. Amy Klobuchar (D-Minnesota) also sent a letter to the Federal Trade Commission in May 2024, seeking an investigation into what she deemed 'potentially anticompetitive conduct.'
Company Argues Claims Invalid
MultiPlan/Claritev asked the court to throw out the complaint, arguing the plaintiffs have not asserted a viable federal antitrust claim because they have not proven antitrust standing nor shown how the company violated antitrust law.
Even if the providers are getting below-market payments, the company said the doctors have failed to allege the lesser payments are due to a harm to competition. Rather, MultiPlan/Claritev's services increase competition by providing another rate calculation option, and its services are further beneficial because they lower costs to third-party payers and patients, the company's attorneys argued.
In addition, the company contended that providers have not been directly injured by the alleged party payer agreement to fix prices because 'they can always seek full payment from the patient.'
However, Kennelly wrote that the providers have alleged a direct injury because the alleged balance billing prohibition prevents providers from seeking the remaining payment from patients and 'shields patients from the consequences of the alleged third-party payor price-fixing agreement.'
If MultiPlan/Claritev's services are harmful or beneficial to competition is a matter for further court analysis, Kennelly also said.
'Whether MultiPlan facilitates a third-party payor price-fixing agreement or is simply another pricing option for payors is a factual dispute that cannot be resolved on a motion to dismiss,' he wrote in his ruling.
The judge, however, dismissed the plaintiffs' unjust enrichment claims against the company. Kennelly wrote the physicians failed to allege an unjust enrichment claim under a specific state law.
A case management conference in the case is scheduled for June 17.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

2 Growth Stocks to Stash and 1 to Question
2 Growth Stocks to Stash and 1 to Question

Yahoo

time20 minutes ago

  • Yahoo

2 Growth Stocks to Stash and 1 to Question

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market's punishment can be swift and severe when trajectories fall. Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. On that note, here are two growth stocks expanding their competitive advantages and one climbing an uphill battle. One-Year Revenue Growth: +25.3% Founded in 2009 by enterprise software veteran Tom Seibel, (NYSE:AI) provides software that makes it easy for organizations to add artificial intelligence technology to their applications. Why Does AI Fall Short? 15.5% annual revenue growth over the last three years was slower than its software peers Extended payback periods on sales investments suggest the company's platform isn't resonating enough to drive efficient sales conversions Historical operating margin losses point to an inefficient cost structure stock price of $25.72 implies a valuation ratio of 7.4x forward price-to-sales. Dive into our free research report to see why there are better opportunities than AI. One-Year Revenue Growth: +32.3% Founded in 2014 and named after the dreaded first day of the work week, (NASDAQ:MNDY) is a software-as-a-service platform that helps organizations plan and track work efficiently. Why Is MNDY a Good Business? ARR trends over the last year show it's maintaining a steady flow of long-term contracts that contribute positively to its revenue predictability Software is difficult to replicate at scale and results in a best-in-class gross margin of 89.5% Strong free cash flow margin of 30.4% enables it to reinvest or return capital consistently is trading at $305 per share, or 12.7x forward price-to-sales. Is now a good time to buy? Find out in our full research report, it's free. One-Year Revenue Growth: +20% Founded in 2010 and named for a combination of 'docs' and 'proximity', Doximity (NYSE: DOCS) is the leading social network for U.S. medical professionals. Why Should DOCS Be on Your Watchlist? Billings have averaged 23.5% growth over the last year, showing it's securing new contracts that could potentially increase in value over time Well-designed software integrates seamlessly with other workflows, enabling swift payback periods on marketing expenses and customer growth at scale DOCS is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $58.44 per share, Doximity trades at 19x forward price-to-sales. Is now the right time to buy? See for yourself in our comprehensive research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free.

St. Pete consignment shop abruptly closes, thousands of dollars in designer goods missing
St. Pete consignment shop abruptly closes, thousands of dollars in designer goods missing

Yahoo

time21 minutes ago

  • Yahoo

St. Pete consignment shop abruptly closes, thousands of dollars in designer goods missing

The Brief Retreat Consignment store closed without warning. Sellers who had their goods on consignment are now missing. The entire store has been completely cleared out. ST. PETERSBURG, Fla. - Thousands of dollars' worth of designer goods are missing from a St. Petersburg consignment shop. The store, Retreat Consignment, abruptly closed without any warning and now several sellers want to know where their stuff is and how to get it back. What we know Detectives spoke with one of the sellers on Monday. He's out thousands of dollars in art pieces. Dozens more on social media are missing designer shoes and bags worth thousands. The shop is empty, and the store owners are nowhere to be found. Follow FOX 13 on YouTube Rich Goren has been collecting original art pieces for years. "These are just two of the examples of them, but you can see the high quality," Goren said. He's sold several on consignment at the Retreat consignment shop on Central Avenue in St. Pete. READ: St. Pete man sailing over 5,500 miles for Ronald McDonald House Charities "We would be in the store pretty often and we would see that our stuff was still there," Goren said. Last week he noticed the store was completely empty. His stuff was nowhere to be found. Two art pieces and two pairs of designer shoes worth about $17,000 altogether are now missing. "I hope for the best, maybe sitting in a warehouse and they want to return everything. That's fine. That would be the best case scenario. But the fact that you have a business, people entrusting you with their valuables and you just take off. Come on. That's not great," Goren said. What they're saying The stores yelp page is now filled with reviews from frustrated sellers with similar stories. MORE: St. Pete approves projects to make sewer system more resilient "I am BESIDE myself that they closed their doors and took off with all of my items," one reviewer wrote. "There has been no communication as to how they are going to get their clients items, and money owed, back to them," another reviewer wrote. "One of the employees reached out to me, I won't say her name, but she said, oh my gosh, I feel awful, we all do, we haven't paid, and it was unexpected. We thought they might sell the store, but we also thought they would be transparent about everything. There's no reason for them not to be calling," Goren said. Goren reported it to the St. Pete Police Department on Monday. Detectives are encouraging any other sellers who also had their items taken to reach out. Goren has tried to reach the shop owners multiple times, but his calls and emails have all went unanswered. "It's a civil case if they have it, and they're not returning it quickly enough and so that's where that lands. So I don't know what it is. I just know that we just always try to do right by people and I expect that they seem like really good people to us but this isn't looking good," Goren said. READ: More affordable housing coming to South St. Pete with Habitat for Humanity partnership Timeline The store closed sometime in March. Goren has tried to contact the owners multiple times via email and phone, but his calls went unanswered. Sellers who had items not returned are encouraged to file a report with St. Pete Police. The Source The information in this story was gathered by FOX 13's Jordan Bowen. WATCH FOX 13 NEWS: STAY CONNECTED WITH FOX 13 TAMPA: Download the FOX Local app for your smart TV Download FOX Local mobile app:Apple |Android Download the FOX 13 News app for breaking news alerts, latest headlines Download the SkyTower Radar app Sign up for FOX 13's daily newsletter

Musk's Banker Michael Grimes Sells SpaceX, Anduril for Trump Job
Musk's Banker Michael Grimes Sells SpaceX, Anduril for Trump Job

Bloomberg

time25 minutes ago

  • Bloomberg

Musk's Banker Michael Grimes Sells SpaceX, Anduril for Trump Job

Michael Grimes, the veteran technology investment banker who helped Elon Musk buy Twitter in 2022, reported assets worth as much as $98 million in a financial disclosure as part of his new role at the Commerce Department. Grimes reported nearly $67 million of income, stock and accrued vacation payout from Morgan Stanley, where he worked for roughly 30 years as a managing director and a co-head of global technology investment banking. That total includes the $56 million he realized from selling restricted stock units that vested after he left in February. Grimes no longer owns shares in the company, according to his disclosure.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store